Jay Van Andel Award for Outstanding Achievement in Parkinson’s Disease Research
The Jay Van Andel Award for Outstanding Achievement in Parkinson’s Disease Research was established in 2012 in memory of Van Andel Institute founder Jay Van Andel, who battled Parkinson’s disease for a decade before his death in 2004. The award is given to scientists who have made outstanding contributions to Parkinson’s disease research and who have positively impacted human health.
The central goal of Dr. Sidransky’s research in the Section of Molecular Neurogenetics is to understand and to optimize treatment for a rare single gene disorder, Gaucher disease, and to apply the insights gained towards a better understanding of Parkinson disease, a common complex disorder. As a physician, she uses a translational approach, integrating both clinical and basic science research, utilizing molecular and protein analyses, cellular and animal models, genomic strategies, high-throughput screens, imaging, and patient studies to achieve her goals. Her research resulted in the paradigm-shifting discovery of a link between Gaucher disease and Parkinson disease. Mutations in the gene encoding glucocerebrosidase (GBA1) are now the most common known genetic risk factor for parkinsonism, including both Parkinson disease and other Lewy body disorders, and Dr. Sidransky spearheaded two large international multicenter collaborations definitive establishing this association, published in the New England Journal of Medicine and JAMA Neurology. Her laboratory and clinical team have led ground-breaking work on GBA1-related parkinsonism using patient samples, mouse models and induced pluripotent stem cell lines. They have contributed to a recognition of the role of lysosomal pathways in neurodegenerative disorder and have developed small molecule chaperones that enhance the delivery of glucocerebrosidase to the lysosome and decrease alpha-synuclein levels in neurons. Moreover, they have carefully evaluated patients with both Gaucher disease and parkinsonism,and have longitudinally followed a large cohort of at-risk individuals, performing periodic clinical, imaging and biochemical assessments. Thus, exploring the bases for this association is yielding new insights into the pathogenesis and treatment of both Gaucher disease and Parkinson disease.
About Jay Van Andel
Entrepreneur and philanthropist Jay Van Andel, perhaps best known as the co-founder of Amway, founded Van Andel Institute in 1996 with his wife Betty. Mr. Van Andel saw opportunity in the landscape of his hometown of Grand Rapids, Michigan, and imagined a thriving center for biomedical research, health care and the life sciences industry. He forged ahead in pursuing this dream despite his diagnosis of Parkinson’s, which eventually took his life in 2004.
In his autobiography, An Enterprising Life, Mr. Van Andel wrote, “Research into the causes and potential cures for Alzheimer’s, Parkinson’s, and other diseases is promising but requires much more support…I hope that my own contributions to medical research will be followed by increased support from other entrepreneurs, charitable foundations, and concerned individuals.”
2018 — K. Ray Chaudhuri, M.D., FRCP, D.Sc.
2017 — J. William Langston, M.D.
2016 — Stanley Fahn, M.D.
2015 — Robert Nussbaum, M.D., and Maria Grazia Spillantini, Ph.D., FMedSci, FRS
2014 — Andrew John Lees, M.D., FRCP, FMedSci
2013 — Alim-Louis Benabid, M.D., Ph.D.
2012 — Andrew Singleton, Ph.D.